Factors Associated With Clinical Trial Participation in Adult Hematopoietic Stem Cell Transplantation Recipients: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fowler Tamryn F, Brazauskas Ruta, Patel Jinalben, Rangarajan Hemalatha G, Michelis Fotios V, Battiwalla Minoo, Lehmann Leslie E, Stefanski Heather E, Dias Ajoy L, Sharma Akshay, Beitinjaneh Amer, Zeidan Amer M, Gómez-De León Andrés, Saad Ayman, Hamilton Betty K, Marks David I, Rizzieri David A, Szwajcer David, Lad Deepesh P, Hildebrandt Gerhard C, Hashem Hasan, Murthy Hemant S, Liu Hongtao, Preussler Jaime M, Yared Jean A, Aljurf Mahmoud, de Lima Marcos, Krem Maxwell M, Herr Megan M, Solh Melhem, Abid Muhammad Bilal, Ramanathan Muthalagu, El Jurdi Najla, Khera Nandita, Majhail Navneet S, Lulla Premal, Seo Sachiko, Hong Sanghee, Chhabra Saurabh, Ganguly Siddhartha, Gergis Usama, Agrawal Vaibhav, El-Jawahri Areej R, Saber Wael
Аннотация
METHODS: We conducted a retrospective study using Center for International Blood and Marrow Transplant Research (CIBMTR) data from US adults aged 18-75 years who underwent autologous or allogeneic HSCT between 2013 and 2019 (N=84,151; autologous: n=51,133; allogeneic: n=33,018). Logistic regression models assessed predictors of participation, while Cox models evaluated associations with OS.
RESULTS: Trial participation was 2.0% among patients undergoing autologous HSCT and 11.1% among those undergoing allogeneic HSCT. Among autologous recipients, greater comorbidity burden was associated with lower odds of participation. Patients with multiple myeloma had higher odds than those with non-Hodgkin lymphoma (odds ratio [OR], 1.25; P=.01). Among allogeneic recipients, older adults had higher odds of participation (eg, OR, 2.19 for age ≥70 vs 18-19 years; P<.0001), as did non-Hispanic Black patients compared with non-Hispanic White patients (OR, 1.35; P=.0002). Participation was higher with cord blood grafts, mismatched unrelated donors, and certain diagnoses (eg, sickle cell disease). Lower participation was observed for severe aplastic anemia and haploidentical or peripheral blood grafts. Trial participation was not associated with OS in either group.
CONCLUSIONS: Clinical trial participation remains low, particularly among autologous HSCT recipients, younger adults, and patients with specific diagnoses. Findings highlight the need to broaden trial eligibility, enhance outreach, and ensure equity in trial access to promote generalizable, patient-centered evidence in HSCT.